ReviewArthritis research & therapy2013
IL-10-producing regulatory B cells (B10 cells) in autoimmune disease.
Review in Arthritis research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 1 synthesis or guideline pooled it, 292 citations in OpenAlex.
- Association between interleukin-10-819T/C polymorphism and risk of ischemic stroke: A meta-analysis.Medicine · 2020Pooled it
- Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2015Trial
- Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency.Journal of clinical lipidologyTrial
- B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.Oncoimmunology · 2026Review
- Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study.PLoS computational biology · 2026Article
- Non-canonical NF-κB drives a fate switch from germinal center to early effector B cells.iScience · 2026Article
- Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells.Nature communications · 2026Article
- Dysregulated expression of PSGL-1 and ADAM8 in Sjögren's disease: potential contribution to disease pathogenesis.Frontiers in immunology · 2026Article
- Roles of immune cell metabolism in rheumatoid arthritis.Frontiers in immunology · 2026Review
- The pivotal role of immunometabolism in diabetic neuropathy and its potential therapeutic strategies.Frontiers in endocrinology · 2026Review
- TIGITFrontiers in immunology · 2026Review
- Immunomodulatory and anti-inflammatory potential of S-nitrosoglutathione (GSNO) in multiple sclerosis: a review of mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
- Article
- Ursodeoxycholic Acid Attenuates B Cell Susceptibility to SARS-CoV-2 Spike Protein by Interfering Its Binding to ACE2.Biomolecules & therapeutics · 2025Article
- The vital role of CD19Advances in rheumatology (London, England) · 2025Article
- B10 cells promote pro-resolving macrophage function through direct cell-cell contact and IL-10 secretion in Raw 264.7 cells.International immunology · 2025Article
- Genetic prediction of immune cells, inflammatory proteins, and metabolite-mediated association between gut microbiota and COPD: a Mendelian randomization study.Scientific reports · 2025Article
- CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells.Clinical and experimental immunology · 2025Article
- Decreased IL-10R-expressing B Cells in breast cancer patients: a potential biomarker for early cancer detection.American journal of clinical and experimental immunology · 2025Article
- The Multifaceted Impact of Bioactive Lipids on Gut Health and Disease.International journal of molecular sciences · 2024Review
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
B cell abnormalities contribute to the development and progress of autoimmune disease. Traditionally, the role of B cells in autoimmune disease was thought to be predominantly limited to the production of autoantibodies. Nevertheless, in addition to autoantibody production, B cells have other functions potentially relevant to autoimmunity. Such functions include antigen presentation to and activation of T cells, expression of co-stimulatory molecules and cytokine production. Recently, the ability of B cells to negatively regulate cellular immune responses and inflammation has been described and the concept of regulatory B cells has emerged. A variety of cytokines produced by regulatory B cell subsets have been reported, with IL-10 being the most studied. In this review, this specific IL-10-producing subset of regulatory B cells has been labeled B10 cells to highlight that the regulatory function of these rare B cells is mediated by IL-10, and to distinguish them from other B cell subsets that regulate immune responses through different mechanisms. B10 cells are a functionally defined subset currently identified only by their competency to produce and secrete IL-10 following appropriate stimulation. Although B10 cells share surface markers with other previously defined B cell subsets, currently there is no cell surface or intracellular phenotypic marker or set of markers unique to B10 cells. The recent discovery of an effective way to expand B10 cells ex vivo opens new horizons in the potential therapeutic applications of this rare B cell subset. This review highlights the current knowledge on B10 cells and discusses their potential as novel therapeutic agents in autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.